Ibrutinib is approved for pediatric patients with chronic graft versus host disease, including a new oral suspension

Share This Post

Sept 2022: Ibrutinib (Imbruvica, Pharmacyclics LLC) was approved by the Food and Drug Administration for use in paediatric patients with chronic graft versus host disease (cGVHD) who are younger than 1 year old and have failed one or more lines of systemic therapy. Oral solution, pills, and capsules are examples of formulations.

Ibrutinib’s efficacy was assessed in iMAGINE (NCT03790332), an open-label, multi-center, single-arm trial for children and young adults with moderate or severe cGVHD. Participants ranged in age from 1 year to less than 22 years. 47 patients needed extra treatment after one or more lines of systemic medication failed and were enrolled in the trial. If genitourinary involvement in a single organ was the only sign of cGVHD, patients were excluded.

The average patient age was 13 years (range, 1 to 19). The following are some of the 47 patients’ demographics: 70% of the population is male, 36% is White, 9% is Black or African American, and 55% is unreported.

The overall response rate (ORR) through Week 25 served as the primary effectiveness outcome indicator. According to the 2014 NIH Consensus Development Project Response Criteria, ORR includes full or partial replies. By Week 25, ORR had reached 60% (95% CI: 44, 74). The average time it took for a response to be given was 5.3 months (95% CI: 2.8, 8.8). The median duration for cGVHD was 14.8 months (95% CI: 4.6, not evaluable) from the first response to death or new systemic treatments.

Anemia, musculoskeletal pain, pyrexia, diarrhoea, pneumonia, abdominal pain, stomatitis, thrombocytopenia, and headache were the most frequent adverse events (20%), as were pyrexia, diarrhoea, pneumonia, abdominal pain, and stomatitis.

The recommended dose of IMBRUVICA is 420 mg orally once daily for patients 12 years of age and older with cGVHD and 240 mg/m2 orally once daily (up to a dose of 420 mg) for patients 1 to less than 12 years of age with cGVHD, until cGVHD progression, recurrence of an underlying malignancy, or unacceptable toxicity.

View full prescribing information for Imbruvica.

 

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Polatuzumab
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form

https://cancerfax.com/